Drucken - Print

Publikationen


Abdrucke der Artikel können jederzeit gerne elektronisch über sebastian.bauer@uni-due.de angefordert werden.

 

 

Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage?  Heinemann M, Ranft A, Langer T, Jürgens H, Kreyer J, Vieth V, Schäfers M, Weckesser M, Simon T, Hassenpflug W, Corbacioglu S, Bielack S, Mayer-Steinacker R, Kühne T, van den Berg H, Gelderblom H, Bauer S, Stegger L, Dirksen U.

Pediatr Blood Cancer 2018 Jul;65(7):e27011.

 

 

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.  Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkovski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 May 28

 

 

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.  Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkovski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 May 28

 

 

Options for treating different soft tissue sarcoma subtypes.  Ray-Coquard I, Serre D, Reichardt P, Martín-Broto J, Bauer S.

Future Oncol 2018 May;14(10s):25-49.

 

 

The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.  Schöffski P, Wozniak A, Leahy MG, Aamdal S, Rutkowski P, Bauer S, Richter S, Grünwald V, Debiec-Rychter M, Sciot R, Geoerger B, Marréaud S, Collette S, Nzokirantevye A, Strauss SJ.

Eur J Cancer 2018 May;94:156-167.

 

 

Survivin is a novel transcription regulator of KIT and is downregulated by miRNA-494 in gastrointestinal stromal tumors.  Yun S, Kim WK, Kwon Y, Jang M, Bauer S, Kim H.

Int J Cancer 2018 May 15;142(10):2080-2093.

 

 

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.  Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2018 May 5.

 

 

Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).  Montemurro M, Cioffi A, Dômont J, Rutkowski P, Roth AD, von Moos R, Inauen R, Toulmonde M, Burkhard RO, Knuesli C, Bauer S, Cassier P, Schwarb H, Le Cesne A, Koeberle D, Bärtschi D, Dietrich D, Biaggi C, Prior J, Leyvraz S.

Cancer 2018 Apr 1;124(7):1449-1454.

 

 

Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey.  Rothermundt C, Fischer GF, Bauer S, Blay JY, Grünwald V, Italiano A, Kasper B, Kollár A, Lindner LH, Miah A, Sleijfer S, Stacchiotti S, Putora PM.

Oncologist 2018 Apr;23(4):461-467.

 

 

Head and Neck Kaposi Sarcoma: Clinicopathological Analysis of 11 Cases.  Agaimy A, Mueller SK, Harrer T, Bauer S, Thompson LDR.

Head Neck Pathol. 2018 Mar 5.

 

 

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.  Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthoney A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S, Stacchiotti S.

Ann Oncol. 2018 Mar 1;29(3):758-765.

 

 

Integrative genomic and transcriptomic analysis of leiomyosarcoma.  Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M, Zapatka M, Ernst A, Kleinheinz K, Schlesner M, Sieverling L, Klink B, Schröck E, Hoogenboezem RM, Kasper B, Heilig CE, Egerer G, Wolf S, von Kalle C, Eils R, Stenzinger A, Weichert W, Glimm H, Gröschel S, Kopp HG, Omlor G, Lehner B, Bauer S, Schimmack S, Ulrich A, Mechtersheimer G, Rippe K, Brors B, Hutter B, Renner M, Hohenberger P, Scholl C, Fröhling S.

Nat Commun. 2018 Jan 10;9(1):144.

 

 

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. Schöffski P, Wozniak A, Escudier B, Rutkowski P, Anthoney A, Bauer S, Sufliarsky J, van Herpen C, Lindner LH, Grünwald V, Zakotnik B, Lerut E, Debiec-Rychter M, Marréaud S, Lia M, Raveloarivahy T, Collette S, Albiges L.

Eur J Cancer. 2017 Dec;87:147-163.

 

 

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.  Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2017 Dec 1;28(12):3000-3008.

 

 

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.  Kaitsiotou H, Keul M, Hardick J, Mühlenberg T, Ketzer J, Ehrt C, Krüll J, Medda F, Koch O, Giordanetto F, Bauer S, Rauh D.J

Med Chem. 2017 Nov 9;60(21):8801-8815.

 

 

Pulmonary metastasectomy for sarcoma-Essen experience.  Gafencu DA, Welter S, Cheufou DH, Ploenes T, Stamatis G, Stuschke M, Theegarten D, Taube C, Bauer S, Aigner C.

J Thorac Dis. 2017 Oct;9(Suppl 12):S1278-S1281.

 

 

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A.gner AJ, Kindler H, Gelderblom H, Schöffski P, Bauer S, Hohenberger P, Kopp HG, Lopez-Martin JA, Peeters M, Reichardt P, Qin A, Nippgen J, Ilaria RL, Rutkowski P.

Br J Cancer 2017 Oct 24;117(9):1278-1285.

 

 

Integrated 18F-FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial.  Erfanian Y, Grueneisen J, Kirchner J, Wetter A, Podleska LE, Bauer S, Poeppel T, Forsting M, Herrmann K, Umutlu L.

Eur J Nucl Med Mol Imaging 2017 Oct;44(11):1823-1831.

 

 

Results for patients with sarcoma not otherwise specified and other diagnoses than Ewing sarcoma treated according to the Euro-EWING 99 trial.  Frank JA, Ranft A, Paulussen M, Juergens H, Kruseova J, Bauer S, Niggli F, Reichardt P, Dirksen U.

Pediatr Blood Cancer 2017 Oct;64(10).

 

 

Preclinical models for translational sarcoma research.  Hamacher R, Bauer S.

Curr Opin Oncol. 2017 Jul;29(4):275-285.

 

 

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Wagner AJ, Kindler H, Gelderblom H, Schöffski P, Bauer S, Hohenberger P, Kopp HG, Lopez-Martin JA, Peeters M, Reichardt P, Qin A, Nippgen J, Ilaria RL, Rutkowski P.

Ann Oncol. 2017 Mar 1;28(3):541-546.

 

 

 

Lower limb function and quality of life after ILP for soft-tissue sarcoma.  Podleska LE, Kaya N, Farzaliyev F, Pöttgen C, Bauer S, Taeger G.

World J Surg Oncol. 2017 Apr 13;15(1):84.

 

 

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.  Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P.

JAMA Oncol. 2017 May 1;3(5):602-609.

 

 

Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).  Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G, Limprecht R, Sommer M, Dimitrakopoulou-Strauss A, Pilz L, Haller F, Hohenberger P.

Eur J Cancer 2017 May;76:60-67.

 

 

MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.  Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Mariño-Enríquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S, Fletcher JA.

Nat Commun. 2017 Mar 8;8:14674.

 

 

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor. Tomassi S, Lategahn J, Engel J, Keul M, Tumbrink HL, Ketzer J, Mühlenberg T, Baumann M, Schultz-Fademrecht C, Bauer S, Rauh D.

J Med Chem. 2017 Mar 23;60(6):2361-2372

 

 

[Isolated limb perfusion for liposarcoma : Histopathological response and subgroup analysis after TNF melphalan-based ILP].[Article in German] Podleska LE, Schwindenhammer B, Grabellus F, Bauer S, Steinau HU, Taeger G.

Chirurg. 2017 Jan 12. doi: 10.1007/s00104-016-0362-3. [Epub ahead of print]

 

 

Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR. Engel J, Becker C, Lategahn J, Keul M, Ketzer J, Mühlenberg T, Kollipara L, Schultz-Fademrecht C, Zahedi RP, Bauer S, Rauh D.

Angew Chem Int Ed Engl. 2016 Aug 26;55(36):10909-12. doi: 10.1002/anie.201605011

 

 

Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments. Pogorzelski M, Falkenhorst J, Bauer S.

Curr Opin Oncol. 2016 Jul;28(4):331-7. doi: 10.1097/CCO.0000000000000303

 

 

Sustained Mutant KIT Activation in the Golgi Complex Is Mediated by PKC-θ in Gastrointestinal Stromal Tumors. Kim WK, Yun S, Park CK, Bauer S, Kim J, Lee MG, Kim H.

Clin Cancer Res. 2016 Jul 20. doi: 10.1158/1078-0432.CCR-16-0521.

 

 

Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib. Falkenhorst J,Grunewald S, Mühlenberg T, Marino-Enriquez A, Reis AC, Corless C, Heinrich M, Treckmann J, Podleska LE, Schuler M, Fletcher JA, Bauer S.

Oncotarget. 2016 Jul 5;7(27):41390-41403. doi: 10.18632/oncotarget.9159.

 

 

Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01). Kasper B, Gruenwald V, Reichardt P, Bauer S, Hohenberger P, Haller F.

Ann Surg Oncol. 2016 Jun;23(6):1924-7. doi: 10.1245/s10434-016-5132-4.

 

 

Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence? Eriksson M, Reichardt P, Sundby Hall K, Schütte J, Cameron S, Hohenberger P, Bauer S, Leinonen M, Reichardt A, Rejmyr Davis M, Alvegård T, Joensuu H.

Eur J Cancer. 2016 May;59:128-33. doi: 10.1016/j.ejca.2016.02.021.

 

 

HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat. Angelika Ihle M, Merkelbach-Bruse S, Hartmann W, Bauer S, Ratner N, Sonobe H, Nishio J, Larsson O, Åman P, Pedeutour F, Taguchi T, Wardelmann E, Buettner R1, Schildhaus

J Pathol Clin Res. 2016 Feb 5;2(2):59-71. doi: 10.1002/cjp2.35

 

 

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial  Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Jörg T. Hartmann, Daniel Pink, Giuliano Ramadori, Peter Hohenberger, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Eva Wardelmann, Bengt Nilsson, Harri Sihto, Petri Bono, Raija Kallio, Jouni Junnila, Thor Alvegård and Peter Reichardt

J Clin Oncol.  2016 Jan 20;34(3):244-50. doi:10.1200/JCO.2015.62.9170.

 

 

Individualisierte Therapie von Sarkomen - Standards und Perspektiven   Prof. Dr. Sebastian Bauer

UNI-MED Science 1. Auflage 2015 ISBN: 978-3-8374-1505-6

 

 

Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway.  Murali R, Chandramohan R, Möller I, Scholz SL, Berger M, Huberman K, Viale A, Pirun M, Socci ND, Bouvier N, Bauer S, Artl M, Schilling B, Schimming T, Sucker A, Schwindenhammer B, Grabellus F, Speicher MR, Schaller J, Hillen U, Schadendorf D, Mentzel T, Cheng DT, Wiesner T, Griewank KG

Oncotarget 2015 Nov 3;6(34):36041-52. doi: 10.18632/oncotarget.5936.

 

 

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.  Sebastian Bauer,  Heikki Joensuu

Drugs 2015 Aug;75(12):1323-34. doi: 10.1007/s40265-015-0440-8.

 

 

miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. Michaela Angelika Ihle, Marcel Trautmanna, Helen Kuenstlinger, Sebastian Huss,1, Carina Heydt, Jana Fassunke, Eva Wardelmann,

Sebastian Bauer, Hans-Ulrich Schildhaus, Reinhard Buettner, Sabine Merkelbach-Bruse

Mol Oncol. 2015 Aug;9(7):1421-33. doi: 10.1016/j.molonc.2015.03.013

 

 

Covalent-Allosteric Kinase Inhibitors  Jörn Weisner, Rajesh Gontla, Leandi van der Westhuizen, Sebastian Oeck, Julia Ketzer, Petra Janning, Andre Richters, Thomas Mühlenberg, Zhizhou Fang, Abu Taher,Verena Jendrossek, Stephen C. Pelly, Sebastian Bauer, Willem A. L. van Otterlo, and Daniel Rauh

Angew. Chemie 2015 Jun 25; doi: 10.1002/anie.201502142

 

 

Inhibition of KIT-glycosylation by 2-deoxyglucose abrogates KIT-signaling and combination with ABT-263 synergistically induces apoptosis in gastrointestinal stromal tumor.  Mühlenberg T, Grunewald S, Treckmann J, Podleska L, Schuler M, Fletcher JA, Bauer S

PLoS One. 2015 Mar 17;10(3):e0120531. doi: 10.1371/journal.pone.0120531.

 

Gastrointestinale Stromatumoren (GIST) – Neues zu Pathologie, Chirurgie und medikamentöser Therapie  A. Agaimy, S. Bauer, A. Beham, J. Bertolini, F. Haller, R. Koschny, J. Maier, M. Montemurro, D. Perez, I.-M. Schaefer, H.-U. Schildhaus, C.Wurst, S. Cameron

Z Gastroenterol. 2015 Mar;53(3):235-43. doi: 10.1055/s-0034-1385711.

 

 

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, Serrano C, Eilers G, Zhu M, Ketzer J, Wardwell S, Ning Y, Song Y, Kohlmann A, Wang F, Clackson T, Heinrich MC, Fletcher JA, Bauer S, Rivera VM.

Clin Cancer Res. 2014 Nov 15;20(22):5745-55. doi: 10.1158/1078-0432.

 

 

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.  Joensuu H1, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, Dematteo RP, Reichardt P

Cancer. 2014 Apr 15. doi: 10.1002/cncr.28669. [Epub ahead of print] 

 

 

Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Kasper B, Sleijfer S, Litière S, Marreaud S, Verweij J, Hodge RA, Bauer S, Kerst JM, van der Graaf WT

Ann Oncol. 2014 Mar;25(3):719-24. doi: 10.1093/annonc/mdt586. 

 

 

A Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - analysis of prognostic factors (EORTC-STBSG collaborative study).Bauer S, Rutkowski R, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen B, Kerst M, Fiore M, Nyckowski P, Hoiczyk M, Cats A, Casali PG, Treckmann J, Coevorden F, Gronchi A

 Eur J Surgl Oncol. Volume 40, Issue 4, April 2014, Pages 412–419

 

 

Phase I Study of Panobinostat and Imatinib in Patients with Treatment-Refractory Metastatic Gastrointestinal Stromal Tumors. Bauer S., Hilger R-A., Mühlenberg T., Grabellus F., Nagarajah J., Hoiczyk M., Reichardt A., Ahrens M., Reichardt P, Grunewald S., Scheulen M.E.,Pustowka A., Bock E., Schuler M., Pink D.

Brit J of Cancer. 2014 Jan;110(5):1155-62. doi: 10.1038/bjc.2013.826.

 

 

Liposarcomas   Henze J, Bauer S.

Hematol Oncol Clin North Am. 2013 Oct; 27 (5):939-55. doi: 10.1016.

 

 

Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.   Reis H, Hager T, Wohlschlaeger J, Bauer S, Katenkamp K, Katenkamp D, Baba HA.

Hum Pathol. 2013 Oct;44(10):2266-74.

 

 

The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas Schwindenhammer B, Podleska LE, Kutritz A, Bauer S, Sheu SY, Taeger G, Kurt Werner S, Grabellus F.

World J surg Oncol. 2013 Aug 12;11 (1):185. 

 

 

Trabectedin in metastatic soft tissue sarcomas – role of pretreatment and age   Hoiczyk M., Grabellus F., Podleska L., Ahrens M., Schwindenhammer B., Taeger G., Pöttgen C., Schuler M., Bauer S.

Int J Oncol. 2013 Jul;(1) 23-8

 

 

Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design. Richters A, Ketzer J, Getlik M, Grütter C, Schneider R, Heuckmann JM, Heynck S, Sos ML, Gupta A, Unger A, Schultz-Fademrecht C, Thomas RK, Bauer S, Rauh D.

J Med Chem. 2013 Jul 25;56(14):5757-72.  

 

 

DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.   Simon S, Grabellus F, Ferrera L, Galietta LJ, Schwindenhammer B, Muehlenberg T, Taeger G, Eilers G, Treckmann J, Breitenbuecher F, Schuler M, Taguchi T, Fletcher JA, Bauer S.

Cancer Res. 2013 Jun 15;73(12):3661-70.

 

 

Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.   Montemurro M., Gelderblom H., Bitz U., Schutte J., Blay J.Y., Joensuu H., Trent J., Bauer S., Rutkowski P., Duffaud F., Pink D.

Eur J Cancer. 2013 Mar;49(5):1027-31.

 

 

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.   Demetri G.D., Reichardt P., Kang Y.-K., Blay J.-Y., Rutkowski P., Gelderblom H., Hohenberger P., Leahy M., von Mehren M., Joensuu H., Badalamenti G., Blackstein M., Le Cesne A., Schoffski P., Maki R.G., Bauer S., Nguyen B.B., Xu J., Nishida T., Chung J., Kappeler C., Kuss I., Laurent D., Casali P.G.

Lancet. 2013 Jan 26;381(9863):295-302. 

 

 

Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas  Grabellus F., Podleska L.E., Sheu S.-Y., Bauer S., Pottgen C., Kloeters C., Hoiczyk M., Lauenstein T.C., Schmid K.W., Taeger G.

Eur J Surg Oncol. 2013 Jan;39(1):61-7

 

 

Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas.   Grabellus F., Podleska L.E., Sheu S.-Y., Bauer S., Pottgen C., Kloeters C., Hoiczyk M., Lauenstein T.C., Schmid K.W., Taeger G.

Eur J Surg Oncol. 2013 Jan;39(1):61-7.

 

 

Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study.   Leahy M., Garcia del muro X., Reichardt P., Judson I., Staddon A., Verweij J., Baffoe-Bonnie A., Jonsson L., Musayev A., Justo N., Burke T., Blay J.Y., SABINE investigators

Ann Oncol. 2012 Oct;23(10):2763-70.

 

 

Growth patterns of lung metastases from sarcoma: prognostic and surgical implications from histology.   Welter S, Grabellus F, Bauer S, Schuler M, Eberhardt W, Tötsch M, Stamatis G.

Interact Cardiovasc Thorac Surg. 2012 Oct;15(4):612-7.

 

 

Pemetrexed in patients with refractory soft tissue sarcoma: a non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005.   Hartmann JT, Bauer S, Egerer G, Horger MS, Kopp HG, Grünwald V, Mayer F.

Invest New Drugs. 2013 Feb;31(1):167-74.

 

 

p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.     Henze J, Mühlenberg T, Simon S, Grabellus F, Rubin B, Taeger G, Schuler M, Treckmann J, Debiec-Rychter M, Taguchi T, Fletcher JA, Bauer S.

PLoS One. 2012;7(5):e37776.

 

 

Intimal sarcoma of the pulmonary artery with unusual findings: A case report.   Hoiczyk M., Iliodromitis K., Bauer S., Konorza T., Philipp S., Bankfalvi A., Gerl J.M., Schuler M., Erbel R.

Clin Res Cardiol. 2012 May;101(5):397-401.

 

 

Individualized tumor therapy and status quo in melanoma.   Bauer S, Schmidberger H, Trefzer U.

Onkologie. 2012;35 Suppl 2:2-6.

 

 

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial.   Joensuu H., Eriksson M., Hall K.S., Hartmann J.T., Pink D., Schutte J., Ramadori G., Hohenberger P., Duyster J., Al-Batran S.-E., Schlemmer M., Bauer S., Wardelmann E., Sarlomo-Rikala M., Nilsson B., Sihto H., Monge O.R., Bono P., Kallio R., Vehtari A., Leinonen M., Alvegard T., Reichardt P.

JAMA. 2012 Mar 28;307(12):1265-72.

 

 

ROR2 is a Novel Prognostic Biomarker and a Potential Therapeutic Target in Leiomyosarcoma and Gastrointestinal Stromal Tumour.    Edris B, Espinosa I, Mühlenberg T, Mikels A, Lee CH, Steigen SE, Zhu S, Montgomery KD, Lazar AJ, Lev D, Fletcher JA, Beck AH, West RB,Nusse R, van de Rijn M

J Pathol. 2012 Jan 4. doi: 10.1002/path.3986.

 

 

Postoperative FDG-PET/CT staging in GIST: is there a benefit following R0 resection?   Hahn S, Bauer S, Heusner TA, Ebeling P, Hamami ME, Stahl A, Forsting M, Bockisch A, Antoch G. 

Eur J Radiol. 2011 Dec;80(3):670-4. Epub 2010 Oct 22

 

 

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes   Schöffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Grünwald V, Sciot R, Dumez H, Blay JY, Le Cesne A, Wanders J, Hayward C, Marreaud S, Ouali M, Hohenberger P; European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) 

Lancet Oncol. 2011 Oct;12(11):1045-52. 

 

 

Growth patterns of lung metastases from sarcomas   Welter S., Grabellus F., Bauer S., Schuler M., Eberhardt W., Totsch M., Stamatis G.

Virchows Arch. 2011 Aug;459(2):213-9.

 

 

Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.    Montemurro M, Bauer S 

Curr Opin Oncol. 2011 Jul;23(4):367-72.

 

 

Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.    Schlemmer M, Bauer S, Schütte R, Hartmann JT, Bokemeyer C, Hosius C, Reichardt P.  

Eur J Med Res. 2011 May 12;16(5):206-12.

 

 

Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-α and melphalan   Grabellus F., Kraft C., Sheu-Grabellus S.-Y.I., Bauer S., Podleska L.E., Lauenstein T.C., Pottgen C., Konik M.J., Schmid K.W., Taeger G.

J Surg Oncol. 2011 Apr;103(5):371-9.

 

 

A novel primary KIT exon 9 single nucleotide substitution c.1427G>T (p.Ser476Ile) in a gastrointestinal stromal tumor.   Grabellus F, Sheu SY, Bauer S, Speich N, Schmid KW, Worm K. 

Virchows Arch. 2010 Nov;457(5):623-5. 

 

 

MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions.   Grabellus F, Konik MJ, Worm K, Sheu SY, van de Nes JA, Bauer S, Paulus W, Egensperger R, Schmid KW. 

Tumour Biol. 2010 Jun;31(3):157-63.  

 

 

Therapeutic Potential of Mdm2 Inhibition in Malignant Germ Cell Tumours.   Bauer S, Mühlenberg T,   Leahy M, Hoiczyk M, Gauler T, Schuler M, Looijenga L. 

Eur Urol. 2010 Apr;57(4):679-87. 

 

 

 Optimizing the Treatment of Gastrointestinal Stromal Tumors: The Roles of Tumor Genotyping, Imatinib Blood-level Testing, and New Therapeutic Strategies.   Michael C. Heinrich, MD, Suzanne George, MD, Sebastian Bauer, MD, Jonathan A. Fletcher, MD

ASCO - ASCO Educational book 2009 May

 

 

Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.    Mühlenberg T, Zhang Y, Wagner AJ, Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M, Fletcher J, Bauer S. 

Cancer Res. 2009 Sep 1;69(17):6941-50.

 

 

Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences.   Grabellus F, Kraft C, Sheu SY, Ebeling P, Bauer S, Lendemans S, Schmid KW, Taeger G. 

Ann Surg Oncol. 2009 Mar;16(3):676-86

 

 

Somatostatin receptor scintigraphy in advanced renal cell carcinoma. Results of a phase II-trial of somatostatine analogue therapy in patients with advanced RCC.   Freudenberg L. S., Gauler T, Görges R, Bauer S, Stergar H, Antoch G, Bockisch A, Schütte J  

Nuklearmedizin. 2008;47(3):127-31.

 

 

Docetaxel and Gemcitabine in the Treatment of Soft Tissue Sarcoma – A Single Center Experience.   Ebeling P, Eisele L, Schuett P, Bauer S, Moritz T, Seeber S, Flasshove M 

Onkologie. 2008 Feb;31(1-2):11-6 

 

 

Role of oncogenic KIT signaling in imatinib-resistant GIST.   Bauer S, Duensing A, Demetri GD, Fletcher JA  

Oncogene 2007 26:7560-8 

 

 

Exatecan is inactive in pretreated patients with advanced soft tissue sarcoma: results of a phase II - study of the EORTC Soft Tissue and Bone Sarcoma Group.   Reichart P, Nielsen OS, Bauer S, Hartmann JT, Schöffski P, Christensen TB, Pink D, Daugaard S, Marreaud S, Van Glabbeke M, Blay JY 

Eur J of Cancer  2007 Apr;43(6):1017-22 

 

 

The challenge of opportunities: how far can and should we go with targeted treatments and modern diagnostics in gastrointestinal stromal tumors?   Bauer S, Lang H 

Eur J Gastroenterol Hepatol. 2007 Aug;19(8):711-3.  19(8): 619-22

 

 

Therapiestrategien in der Onkologie – Beurteilung der Toxizität, des Allgemeinzustandes und der Lebensqualität – Bedeutung der Toxizität für den Verlauf der Chemotherapie.   Bauer S, Schütte J. 

Supportive Therapie in der Onkologie - 2. Auflage. MR Nowrousian (Herausgeber). Zuckschwerdt Verlag, München, (Buchkapitel)

 

 

Gastrointestinale Stromatumoren in "Therapiekonzepte Onkologie"    Bauer S, Schütte J 

S. Seeber, J. Schütte (Herausgeber). Springerverlag, 5. Auflage, 2007. S. 692-712 

 

 

In Vitro Efficacy of HSP90 Inhibition in Imatinib-resistant Gastrointestinal Stromal Tumors.   Bauer S, Yu L, Demetri G, Fletcher J 

Cancer Res. 66: 9153-6 (2006)

 

 

Complete remission with imatinib in metastatic GIST.   Bauer S, Lang H , Schütte J, Hartmann J . 

J of Clin Oncol 23(27):6800-a-6801 (2005)

 

 

Optimization of gene transfer into neonatal rat cardiomyocytes and unmasking of cytomegalovirus promoter silencing.   Bauer S, Maier S, Neyses L, Maass A  

DNA and Cell Biology. 24(6): 381-387 (2005)

 

 

Locally advanced and metastatic soft tissue sarcoma.   Bauer S, Hartmann J  

Critical Reviews in Oncology and Hematology 60: 112-130 (2005)

 

 

Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.   Bauer S, Hartmann JT, Lang H, Grabellus F, de Wit M, Antoch G, Niebel W, Ehrhardt J, Zeth M, Ebeling P, Taeger G, Seeber S, Flasshove M, Schütte HJ 

Intl J of Cancer 117(2): 316-325 (2005)

 

 

Comparison of CT, PET and dual-modality PET/CT imaging for monitoring of Imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.   Antoch G, Freudenberg LS, Bauer S, Kuehl H, Renzing-Koehler K, Goerges R, Schuette J, Bockisch A, Debatin JF Kanja J  

J of Nuc Med 45(3): 357-65 (2004)

 

 

Role of gemcitabine in the treatment of soft tissue sarcoma.   Bauer S, Schütte J 

Onkologie 27(2):180-6 (2004)

 

 

Gastrointestinale Stromatumoren (GIST) - medikamentöse Behandlung mit Imatinib und Therapieüberwachung. Schütte J, Bauer S  

Tumordiagnostik und Therapie 25: 174-176  (IF: 0,8)

 

 

Response to imatinib mesylate of gastrointestinal stromal tumor with very low expression of KITBauer S, Corless C, Heinrich M, Dirsch O, Antoch G, Kanja G, Seeber S, Schütte J

Cancer, Chemotherapy and Pharmacology 51(3): 261-265 (2003)

 

 

Rational Promoter selection for gene transfer into cardiac cellsMaass AH, Langer SJ, Bauer S, Oberdorf-Maass S, Neyses L, Leinwand LA.

J Mol Cell Cardiol2003; 35: 823-83

 

 

Tyrosinkinase-Inhibition bei soliden Tumoren am Beispiel von Imatinib bei GIST.  Bauer S

Onkologie heute 3(24): 25-27 (2003)

 

 

Somatische Mutationen – Gen- und Chromosomendefekte bei sporadischen Tumoren: Lungentumoren. Opalka B, Bauer S, Schütte J

Medizinische Genetik press. medgen 14(2): 139-144 (2002)

 

 

Neoadjuvante Therapie bei Weichteilsarkomen. Bauer S, Schütte J

Onkologe 4: 334-341. (2002)

 

 

Gemcitabine-containing Chemotherapy in the Treatment of Patients with Advanced Soft Tissue Sarcoma   Bauer S, Hartung J, Gauler T, Gocke P, Trarbach T, Flasshove M, Nowrousian MR, Bojko P, Hense J, Seeber S, Schütte J

Tumordiagnostik und Therapie 23: 219-224 (2002)

 

 

Imatinib in Patients with impaired liver function  Bauer S, Hagen V, Pielken HJP, Bojko P, Seeber S, Schütte J

Anticancer Drugs 13(8): 847-9. (2002)